医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗关注国内三抗布局创新药企

甬兴证券有限公司07-17

上周（2025 年7 月7 日-7 月11 日），A 股申万医药生物上涨1.82%，板块整体跑赢沪深300 指数1pct，跑输创业板综指数0.39pct。在申万31 个一级子行业中，医药板块周涨跌幅排名为第16 位。恒生医疗保健指数上涨0.05%，板块整体跑输恒生指数0.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第9 位。核心观点重磅交易落地，艾伯维引进CD3/BCMA/...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552177419?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552177419","market":"us","top_or_hot":-1,"title":"医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗 关注国内三抗布局创新药企","media":"甬兴证券有限公司","content":"<div>\n<p>上周（2025 年7 月7 日-7 月11 日），A 股申万医药生物上涨1.82%，板块整体跑赢沪深300 指数1pct，跑输创业板综指数0.39pct。在申万31 个一级子行业中，医药板块周涨跌幅排名为第16 位。恒生医疗保健指数上涨0.05%，板块整体跑输恒生指数0.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第9 位。核心观点重磅交易落地，艾伯维引进CD3/BCMA/...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗 关注国内三抗布局创新药企</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗 关注国内三抗布局创新药企\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b><strong>甬兴证券有限公司</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>上周（2025 年7 月7 日-7 月11 日），A 股申万医药生物上涨1.82%，板块整体跑赢沪深300 指数1pct，跑输创业板综指数0.39pct。在申万31 个一级子行业中，医药板块周涨跌幅排名为第16 位。恒生医疗保健指数上涨0.05%，板块整体跑输恒生指数0.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第9 位。核心观点重磅交易落地，艾伯维引进CD3/BCMA/...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DE","symbol_name":"迪尔股份有限公司","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b","article_id":"2552177419","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552177419","pubTimestamp":1752681600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"恒生医疗保健指数上涨0.05%，板块整体跑输恒生指数0.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第9 位。核心观点重磅交易落地，艾伯维引进CD3/BCMA/CD38 管线。投 资建议此次艾伯维引进CD3/BCMA/CD38三抗，进一步点燃了三抗赛道的热情，建议关注国内有三抗布局的企业，如泽璟制药-U、信达生物、神州细胞、基石药业-B、先声药业、汇宇制药-W、恒瑞医药等。风险提示销售不及预期风险，医药政策影响不确定的风险，新药研发失败风险。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"DE":"迪尔股份有限公司","BK4585":"ETF&股票定投概念","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4566":"资本集团","ABBV":"艾伯维公司","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","BK4152":"农用农业机械","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0345781412.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","BK4588":"碎股","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1861214812.USD":"Blackrock Future of Transport A2 USD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","ORR":"Militia Long/Short Equity ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC"},"translate_title":"Pharmaceutical and Biological Industry Weekly: AbbVie introduces CD3/BCMA/CD38 tertiary antibodies to focus on domestic tertiary antibody layout innovative pharmaceutical companies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORR":1,"DE":1,"ABBV":0.9},"content_text":"上周（2025 年7 月7 日-7 月11 日），A 股申万医药生物上涨1.82%，板块整体跑赢沪深300 指数1pct，跑输创业板综指数0.39pct。在申万31 个一级子行业中，医药板块周涨跌幅排名为第16 位。恒生医疗保健指数上涨0.05%，板块整体跑输恒生指数0.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第9 位。核心观点重磅交易落地，艾伯维引进CD3/BCMA/CD38 管线。7 月10 日，艾伯维宣布与Ichnos Glenmark Innovation 的全资子公司IGI Therapeutics 达成独家许可协议，获得其主要资产ISB 2001 在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。根据监管部门的批准，IGI 将获得 7 亿美元的预付款，并有资格获得高达 12.25 亿美元的开发、监管和商业里程碑付款，以及净销售额的分级两位数特许权使用费。ISB 2001 已在I 期研究中展现出治疗潜力。ISB 2001 是一种同类首创的三特异性 T 细胞接合器，靶向骨髓瘤细胞上的 BCMA 和 CD38 以及 T 细胞上的 CD3，用于治疗复发/难治性多发性骨髓瘤，目前处于 1 期。美国食品和药物管理局于2023 年7 月授予ISB 2001 孤儿药认定，并于2025年5 月授予用于治疗复发/难治性骨髓瘤患者的快速通道认定。在 2025 年美国临床肿瘤学会（ASCO） 年会上，公布了ISB2001 的I 期首次人体研究：靶向 BCMAxCD38xCD3 的三特异性抗体，用于复发/难治性多发性骨髓瘤 （RRMM） 患者——剂量递增 （DE） 结果：截至 2025 年1 月 13 日，24 名患者接受了ISB 2001 治疗，涉及 8 个剂量水平 （5-1800 μg/kg），中位随访时间为 6 个月 （范围：2-12）。DL9（2700 μg/kg） 是最后剂量水平，目前正在招募。在24 例患者中，中位年龄为 66 岁；58% 为男性，83% 为白人，既往接受过 6 线治疗的中位数为 6 线（范围：3-11）。所有 pts 均为三重暴露，17/24 （71%）为五重暴露，3/17 为难治性五重暴露 （18%）。没有发生导致治疗中断或死亡的DLT、不良事件 （AE）。8 例 （33%） 患者报告了严重的 AE。在 13 例（54%） 患者中观察到药物相关的 （Gr） 3-4 级 AE， 在 17 例（70.8%） 患者中报告了 CRS，主要是 1-2 级，中位发病时间为 3 天，中位持续时间为 2 天。无神经系统 AE 或 ICAN。所有 8 剂的总体缓解率（ORR） 为 75%，包括严格 CR （sCR） 13%、CR 13%、VGPR 38%、PR 13%。从低至 50 μg/kg （MRD-neg， sCR） 的剂量水平观察到反应，剂量 ≥50 μg/kg 时 ORR 为 82%。中位缓解时间为 36 天。ISB 2001显示接近剂量比例的 PK、> 10 天的半衰期和一致的 T 细胞活化，支持其作用机制。投 资建议此次艾伯维引进CD3/BCMA/CD38三抗，进一步点燃了三抗赛道的热情，建议关注国内有三抗布局的企业，如泽璟制药-U、信达生物、神州细胞、基石药业-B、先声药业、汇宇制药-W、恒瑞医药等。风险提示销售不及预期风险，医药政策影响不确定的风险，新药研发失败风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552177419","isCrawlerRequest":true}

医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗 关注国内三抗布局创新药企

精彩评论

医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗关注国内三抗布局创新药企